<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604863</url>
  </required_header>
  <id_info>
    <org_study_id>HGS1036-C1118</org_study_id>
    <nct_id>NCT01604863</nct_id>
  </id_info>
  <brief_title>A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies</brief_title>
  <official_title>Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Human Genome Sciences Inc., a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the maximally tolerated dose (MTD) of
      HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus
      carboplatin, cisplatin plus etoposide, or docetaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of 3 regimens each containing 2 dose levels of HGS1036 and full dose
      chemotherapy. Patients will be treated in sequence with HGS1036 at planned dose levels of 10
      mg/kg and 20 mg/kg. Patients who demonstrate stable disease or better may continue to receive
      HGS1036 until progressive disease, unacceptable toxicity, patient requests discontinuation of
      study treatment, or the Investigator feels further treatment is not in the patient's best
      interest. After discontinuation of HGS1036, subjects will be followed for 30 days after the
      last dose of HGS1036 for safety. The end of study will be defined as 1 year after the last
      subject begins treatment of HGS1036. Any subject still receiving HGS1036 at this pre-defined
      end of study, may continue to receive HGS1036, but the only study assessments required will
      be for safety.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study suspended prior to enrollment
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 1 year or longer if indicated.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 1 year or longer if indicated.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGS1036 + Paclitaxel + Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGS1036 + Cisplatin + Etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGS1036 + Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGS1036 + Paclitaxel + Carboplatin</intervention_name>
    <description>HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGS1036 + Cisplatin + Etoposide</intervention_name>
    <description>HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGS1036 + Docetaxel</intervention_name>
    <description>HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a histological or cytological diagnosis of malignant solid neoplasm requiring
             systemic chemotherapy.

          -  Age ≥18 years.

          -  ECOG performance status 0-1.

          -  Adequate organ function.

          -  Adequate hematological function.

          -  Have the ability to understand the requirements of the study, provide written informed
             consent, and comply with the study protocol procedures.

          -  Consent to collection of previously obtained, archival biopsy or surgical specimens of
             the currently treated malignancy when available.

        Exclusion Criteria:

          -  Significant cardiac disease.

          -  Eye trauma or disease.

          -  Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months
             prior to first dose of HGS1036.

          -  Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of
             HGS1036.

          -  Major surgery within 4 weeks of the first dose of HGS1036.

          -  Prior organ or allogeneic stem cell transplant.

          -  Non-healing or chronic wounds.

          -  Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036.

          -  Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of
             the first dose of HGS1036.

          -  Active CNS involvement by primary or metastatic tumor.

          -  Documented active infection requiring the use of systemic antibiotics.

          -  Pregnancy or lactation.

          -  Known HIV-positive serology, AIDS, or an AIDS-related illness.

          -  Conditions likely to increase the potential for abdominal perforation or fistula
             formation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>October 29, 2012</last_update_submitted>
  <last_update_submitted_qc>October 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Mesothelioma</keyword>
  <keyword>Small Cell lung Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

